Xinhua Pharmaceutical's Alzheimer's Drug Completes Phase I Clinical Trial

MT Newswires Live08-23

Shandong Xinhua Pharmaceutical (HKG:0719, SHE:000756) said its Alzheimer's drug OAB-14 completed Phase I testing and is expected to advance to Phase II within the year.

The drug was manufactured by Shandong Zibo Xincat Pharmaceutical, a unit of the company. It is used to treat mild to moderate Alzheimer's disease, according to a Thursday filing with the Hong Kong Exchange.

Price (HKD): $5.28, Change: $-0.050, Percent Change: -0.94%

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2461557806?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-08-23 17:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2461557806","market":"nz","top_or_hot":-1,"title":"Xinhua Pharmaceutical's Alzheimer's Drug Completes Phase I Clinical Trial","media":"MT Newswires Live","content":"<html><body><p> Shandong Xinhua Pharmaceutical (HKG:0719, SHE:000756) said its Alzheimer's drug OAB-14 completed Phase I testing and is expected to advance to Phase II within the year.</p><p>The drug was manufactured by Shandong Zibo Xincat Pharmaceutical, a unit of the company. It is used to treat mild to moderate Alzheimer's disease, according to a Thursday filing with the Hong Kong Exchange.</p><p>Price (HKD): $5.28, Change: $-0.050, Percent Change: -0.94%</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Xinhua Pharmaceutical's Alzheimer's Drug Completes Phase I Clinical Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nXinhua Pharmaceutical's Alzheimer's Drug Completes Phase I Clinical Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-08-23 17:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shandong Xinhua Pharmaceutical (HKG:0719, SHE:000756) said its Alzheimer's drug OAB-14 completed Phase I testing and is expected to advance to Phase II within the year.The drug was manufactured by ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HKD","symbol_name":"尚乘数科","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2461557806","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2461557806","pubTimestamp":1724404519,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Shandong Xinhua Pharmaceutical  said its Alzheimer's drug OAB-14 completed Phase I testing and is expected to advance to Phase II within the year.The drug was manufactured by Shandong Zibo Xincat Pharmaceutical, a unit of the company. It is used to treat mild to moderate Alzheimer's disease, according to a Thursday filing with the Hong Kong Exchange.Price : $5.28, Change: $-0.050, Percent Change: -0.94%","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HKD":"尚乘数科","000756":"新华制药","00719":"山东新华制药股份","BK4588":"碎股","BK4526":"热门中概股","BK4023":"应用软件","BK0164":"国企混改","BK0239":"医药制造","BK1191":"制药","BK1515":"抗疫概念","BK4585":"ETF&股票定投概念"},"translate_title":"新华制药阿尔茨海默病药物完成I期临床试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HKD":1,"000756":0.9,"00719":0.9},"content_text":"Shandong Xinhua Pharmaceutical (HKG:0719, SHE:000756) said its Alzheimer's drug OAB-14 completed Phase I testing and is expected to advance to Phase II within the year.The drug was manufactured by Shandong Zibo Xincat Pharmaceutical, a unit of the company. It is used to treat mild to moderate Alzheimer's disease, according to a Thursday filing with the Hong Kong Exchange.Price (HKD): $5.28, Change: $-0.050, Percent Change: -0.94%","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2461557806"}